1.	Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: RTOG 1216, NCI-2013-00500, U10CA021661, NCT01810913
2.	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00507, E1305, CDR0000582533, U10CA021115, ECOG-E1305, NCT00588770
3.	Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000651536, RTOG-0920, NCT00956007
4.	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
5.	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000695731, RTOG-1016, NCT01302834
6.	LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.131, 2011-000392-14, NCT01345669
7.	LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.43, 2011-000391-34, NCT01345682
8.	CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000727295, NCCTG-N11C5, N11C5, NCT01545687
9.	Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer Phase: Phase III Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: 201207059, NCT01687413
10.	The Quarterback Trial Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO 12-1050, HS 12-00359, IF 1403412, NCT01706939
11.	A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: X90003, NCT00660218
12.	Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CDR0000634258, SCCC-112008-019, ABX 236-HN08US, 112008-019, NCT00851877
13.	A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: J08101, CA180123, NCT00882583
14.	Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 603EUSA03, NCT00901732
15.	Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 06-121, 1R21CA130241-01A1, NCT00903461
16.	Vitamin D - Celecoxib Therapy Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: CLIN-003-09S, NCT00953849
17.	Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: VCC 0905, NCT00982436
18.	Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-131, NCT01016769
19.	Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx Phase: Phase II, Phase I Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J0988, NA_00026771, NA_00026771, NCT01088802
20.	Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 100180, 10-D-0180, NCT01195922
21.	Study of PX-866 and Docetaxel in Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-866-002, NCT01204099
22.	Symptom Burden in Head and Neck Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 2009-0517, NCT01219673
23.	A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI1761-09, NCT01283334
24.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
25.	E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-702, 2011-000773-31, NCT01332266